SCHEMBL13459944

SCHEMBL13459944

CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4cccc5cnccc45)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.55
▸ FLT4 P35916 4/20 0.55
▸ FLT3 P36888 3/20 0.55
▸ PDGFRA P16234 2/20 0.55
▸ KCNH2 Q12809 2/20 0.55
▸ CCNA2 P20248 3/20 0.51
▸ CDK2 P24941 3/20 0.51
▸ CCNA1 P78396 3/20 0.51
▸ TRPV1 Q8NER1 4/20 0.50
▸ KDR P35968 3/20 0.48
▸ KIT P10721 1/20 0.48
▸ RIPK1 Q13546 2/20 0.48
▸ CDK4 P11802 2/20 0.47
▸ CCND3 P30281 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ NTRK3 Q16288 2/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ RET P07949 1/20 0.46
▸ FGFR1 P11362 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13459602 0.90 NTRK1 (0.52) CSF1RFLT4FLT3PDGFRAKCNH2
SCHEMBL13459592 0.81 RIPK1 (0.69) CSF1RFLT4FLT3TRPV1KDR
SCHEMBL13459840 0.80 BRAF (0.53) CSF1RFLT3KCNH2TRPV1KDR
SCHEMBL13459818 0.79 RET (0.64) CSF1RFLT4FLT3PDGFRACDK2
SCHEMBL3843511 0.79 KDR (0.52) CSF1RFLT4FLT3PDGFRAKCNH2
SCHEMBL13459943 0.78 TEK (0.54) CSF1RFLT3KDRNTRK1
SCHEMBL3166302 0.77 SRC (0.72) CSF1RFLT4FLT3PDGFRAKCNH2
SCHEMBL13632604 0.74 KDR (0.59) TRPV1KDR
SCHEMBL13459594 0.74 HTR2B (0.53) CSF1RFLT4FLT3TRPV1KDR
SCHEMBL13459817 0.73 TRPV1 (0.53) CSF1RFLT4FLT3TRPV1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010032986-A2 NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY 주식회사 이큐스팜 (KR) 2010-03-25 — — WO disclosed
Send feedback